Registered title, quoted from ClinicalTrials.gov
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
An open trial on IgA nephropathy, registered on ClinicalTrials.gov. Led by Sichuan Provincial People's Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06676007, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Primary IgA nephropathy diagnosed by renal biopsy within 3 months
Inclusion criterion 2
Patients who have received systemic immunosuppressive drug treatment within 3 months prior to enrollment
Exclusion criterion 12
Patients who have received any systemic GCS treatment within the past 3 months prior to enrollment
Exclusion criterion 13
Current or previous (within the past 2 years) alcoholism or drug abuse;
Exclusion criterion 15
eGFR≥30ml/min/1.73m2
Inclusion criterion 3
Patients diagnosed with malignant tumors within the past 5 years
Exclusion criterion 8
During the study treatment period and 3-month follow-up period, women who are pregnant, breastfeeding, or unwilling to use highly effective contraception (contraception is only required for women with fertility potential)
Exclusion criterion 17
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06676007, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Target patients aged 18-75, including those aged 18 and 75
- Primary IgA nephropathy diagnosed by renal biopsy within 3 months
- eGFR≥30ml/min/1.73m2
- 24-hour urine protein ≥ 1.0g/d, or UPCR ≥ 0.8 g/g
- Sign informed consent
Exclusion Criteria:
- Including but not limited to secondary IgAN caused by allergic purpura, systemic lupus erythematosus, cirrhosis, rheumatoid arthritis, and ankylosing spondylitis
- Patients who have received kidney transplantation or dialysis
- Patients with other glomerular diseases (such as C3 glomerular disease and/or diabetes nephropathy) and nephrotic syndrome (i.e. proteinuria>3.5 g/d, serum albumin<3.0 g/dl, with or without edema)
- Patients with acute, chronic, or potential infectious diseases, including hepatitis, tuberculosis, human immunodeficiency virus, and chronic urinary tract infections
- Patients with type 1 or type 2 diabetes diagnosed and poorly controlled (HbA1c>8%)
- Patients with a history of unstable angina, grade III or IV congestive heart failure, and/or clinically significant arrhythmias
- Patients with poor blood pressure control (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg)
- Patients diagnosed with malignant tumors within the past 5 years
- Patients with known glaucoma, known cataracts, and/or a history of cataract surgery
- Gastrointestinal diseases that may interfere with the study of drug efficacy or release, such as peptic ulcer disease, inflammatory bowel disease, and chronic diarrhea
- Patients with severe adverse reactions to steroids in the past, including psychiatric symptoms
- Patients who have received systemic immunosuppressive drug treatment within 3 months prior to enrollment
- Patients who have received any systemic GCS treatment within the past 3 months prior to enrollment
- Patients taking potent cytochrome P450 3A4 inhibitors (CYP3A4)
- Current or previous (within the past 2 years) alcoholism or drug abuse;
- Expected lifespan<5 years
- During the study treatment period and 3-month follow-up period, women who are pregnant, breastfeeding, or unwilling to use highly effective contraception (contraception is only required for women with fertility potential)
- Researchers believe that patients who are not suitable for treatment with Nefecon
Quoted from ClinicalTrials.gov, NCT06676007, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06676007, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.